scholarly article | Q13442814 |
P356 | DOI | 10.3748/WJG.V20.I41.15163 |
P8608 | Fatcat ID | release_gwdum4ld75glnj54xicfnpsdxe |
P3181 | OpenCitations bibliographic resource ID | 465055 |
P932 | PMC publication ID | 4223251 |
P698 | PubMed publication ID | 25386066 |
P50 | author | Abelardo Margolles | Q39865763 |
Patricia Ruas-madiedo | Q42829084 | ||
Miguel Gueimonde | Q54402863 | ||
Clara de los Reyes-Gavilan | Q57415893 | ||
Rafael Tojo González | Q108601670 | ||
P2093 | author name string | Adolfo Suárez | |
Marta G Clemente | |||
P2860 | cites work | High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease | Q22250942 |
Probiotics for treating persistent diarrhoea in children | Q24200347 | ||
Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children | Q24202700 | ||
Probiotics for preventing acute upper respiratory tract infections | Q24234353 | ||
Probiotics for maintenance of remission in ulcerative colitis | Q24234400 | ||
Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis | Q24234806 | ||
Probiotics for the prevention of pediatric antibiotic-associated diarrhea | Q24235039 | ||
Probiotics for patients with hepatic encephalopathy | Q24235259 | ||
Probiotics for prevention of necrotizing enterocolitis in preterm infants | Q24235681 | ||
Probiotics for treating acute infectious diarrhoea | Q24236704 | ||
Probiotics for the treatment of bacterial vaginosis | Q24240103 | ||
Interventions for prevention of post-operative recurrence of Crohn's disease | Q24240542 | ||
Probiotics for treating eczema | Q24241429 | ||
Gut-Liver Axis and Sensing Microbes | Q37869765 | ||
Early life: gut microbiota and immune development in infancy. | Q37915055 | ||
The gut microbiota in 2011: Translating the microbiota to medicine. | Q37969933 | ||
Techniques used to characterize the gut microbiota: a guide for the clinician. | Q37997281 | ||
The gut microbiota in IBD. | Q38036078 | ||
The role of the gut microbiota in nutrition and health. | Q38040322 | ||
The role of gut microbiota in the pathogenesis of colorectal cancer | Q38080504 | ||
Influence of fermented milk products, prebiotics and probiotics on microbiota composition and health. | Q38114553 | ||
Microbiota abnormalities in inflammatory airway diseases - Potential for therapy | Q38130813 | ||
VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study | Q39286213 | ||
Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome | Q39348241 | ||
Qualitative and quantitative analyses of the bifidobacterial microbiota in the colonic mucosa of patients with colorectal cancer, diverticulitis and inflammatory bowel disease | Q41820647 | ||
Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy | Q42950499 | ||
Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome | Q43244921 | ||
Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial | Q43363077 | ||
Probiotic VSL#3 prevents antibiotic-associated diarrhoea in a double-blind, randomized, placebo-controlled clinical trial | Q43644098 | ||
Chemotaxonomic analysis of bacterial populations colonizing the rectal mucosa in patients with ulcerative colitis | Q43945848 | ||
Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFα. | Q45169761 | ||
Probiotics for induction of remission in Crohn's disease | Q24242115 | ||
Probiotics for treatment of Clostridium difficile-associated colitis in adults | Q24242821 | ||
Probiotics for induction of remission in ulcerative colitis | Q24242963 | ||
Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis | Q24243033 | ||
Probiotics in infants for prevention of allergic disease and food hypersensitivity | Q24243561 | ||
Probiotics for maintenance of remission in Crohn's disease | Q24244110 | ||
Probiotics for preventing preterm labour | Q24246388 | ||
Enterotypes of the human gut microbiome | Q24489818 | ||
Diversity of the human intestinal microbial flora | Q24544241 | ||
Human gut microbiome viewed across age and geography | Q24602950 | ||
Linking long-term dietary patterns with gut microbial enterotypes | Q24609914 | ||
Therapeutic faecal microbiota transplantation: current status and future developments | Q24629302 | ||
A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses | Q24630221 | ||
Intestinal microbiota in functional bowel disorders: a Rome foundation report | Q24631357 | ||
Metagenomic analysis of the human distal gut microbiome | Q24633486 | ||
Current status and future promise of the human microbiome | Q26865656 | ||
Gut microbiota and gastrointestinal health: current concepts and future directions | Q26865880 | ||
Analysis of the Human Gut Microbiome and Association With Disease | Q26995807 | ||
Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome | Q26999711 | ||
Brain-gut microbiome interactions and functional bowel disorders | Q27014531 | ||
An obesity-associated gut microbiome with increased capacity for energy harvest | Q27860515 | ||
Host-bacterial mutualism in the human intestine | Q27861037 | ||
Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis | Q28251985 | ||
Fecal microbiota transplantation and emerging applications | Q28255756 | ||
Diversity, stability and resilience of the human gut microbiota | Q28274959 | ||
Duodenal infusion of donor feces for recurrent Clostridium difficile | Q28283517 | ||
The Role of the Microbiome in Rheumatic Diseases | Q28284835 | ||
Therapeutic potential of fecal microbiota transplantation | Q28298108 | ||
Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents | Q28300892 | ||
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. | Q35233808 | ||
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis | Q35596222 | ||
Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon | Q35598397 | ||
The bacteriology of pouchitis: a molecular phylogenetic analysis using 16S rRNA gene cloning and sequencing | Q35799373 | ||
Beyond phylotyping: understanding the impact of gut microbiota on host biology | Q35915240 | ||
The 'microflora hypothesis' of allergic diseases | Q36360555 | ||
Microbiota and gut-liver axis: their influences on obesity and obesity-related liver disease | Q36798196 | ||
Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut | Q37097658 | ||
The intestinal microbiota, gastrointestinal environment and colorectal cancer: a putative role for probiotics in prevention of colorectal cancer? | Q37174716 | ||
Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility | Q37226735 | ||
Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients | Q37234016 | ||
Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome | Q37234770 | ||
Specific probiotics alleviate allergic rhinitis during the birch pollen season | Q37262058 | ||
Consumption of fermented milk product with probiotic modulates brain activity | Q37340274 | ||
The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease | Q37490320 | ||
Concepts in familial colorectal cancer: where do we stand and what is the future? | Q37525385 | ||
Infection, inflammation, and the irritable bowel syndrome | Q37589116 | ||
Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea‐predominant irritable bowel syndrome | Q37684406 | ||
Inflammation and colon cancer | Q37737408 | ||
Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective | Q37852406 | ||
Probiotics and Lung Diseases | Q37861945 | ||
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment | Q28710518 | ||
Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients | Q29614261 | ||
Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders | Q29617111 | ||
An update on the use and investigation of probiotics in health and disease | Q30407565 | ||
Comparison of two oral probiotic preparations in a randomized crossover trial highlights a potentially beneficial effect of Lactobacillus paracasei NCC2461 in patients with allergic rhinitis | Q30443010 | ||
Composition, variability, and temporal stability of the intestinal microbiota of the elderly | Q30499047 | ||
Exposure to environmental microorganisms and childhood asthma | Q31000265 | ||
Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease | Q33201542 | ||
Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant faecal bacteria | Q33238568 | ||
Differences in faecal bacterial communities in coeliac and healthy children as detected by PCR and denaturing gradient gel electrophoresis. | Q33301744 | ||
Culture-independent analysis of the gut microbiota in colorectal cancer and polyposis | Q33317609 | ||
Unstable composition of the fecal microbiota in ulcerative colitis during clinical remission | Q33323929 | ||
Imbalances in faecal and duodenal Bifidobacterium species composition in active and non-active coeliac disease | Q33395121 | ||
Microbiomic analysis of the bifidobacterial population in the human distal gut. | Q33419297 | ||
A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. | Q33433931 | ||
Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial | Q33440895 | ||
Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms: a randomised, double-blind, parallel, controlled study | Q33443147 | ||
Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults | Q33450795 | ||
The microbiome in inflammatory bowel disease: current status and the future ahead | Q33664898 | ||
Desulfovibrio Bacterial Species Are Increased in Ulcerative Colitis | Q33715969 | ||
Cross-sectional and longitudinal comparisons of the predominant fecal microbiota compositions of a group of pediatric patients with cystic fibrosis and their healthy siblings. | Q34021561 | ||
A diet low in FODMAPs reduces symptoms of irritable bowel syndrome | Q34038352 | ||
Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey | Q34094839 | ||
Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures | Q34388328 | ||
Facultative to strict anaerobes ratio in the preterm infant microbiota: a target for intervention? | Q34393663 | ||
Manipulation of the microbiota for treatment of IBS and IBD-challenges and controversies | Q34401472 | ||
Cystic fibrosis transmembrane conductance regulator knockout mice exhibit aberrant gastrointestinal microbiota | Q34444065 | ||
The gut microbiota and the liver. Pathophysiological and clinical implications. | Q34489152 | ||
Integrated metagenomics/metaproteomics reveals human host-microbiota signatures of Crohn's disease | Q34499601 | ||
Cystic fibrosis transmembrane conductance regulator (CFTR) allelic variants relate to shifts in faecal microbiota of cystic fibrosis patients. | Q34684122 | ||
Gut microbiota, enteroendocrine functions and metabolism | Q35001608 | ||
Impact of probiotics on risk factors for cardiovascular diseases. A review | Q35031383 | ||
Differential effects of antibiotic therapy on the structure and function of human gut microbiota | Q35055063 | ||
Microbial targets for the development of functional foods accordingly with nutritional and immune parameters altered in the elderly. | Q35113979 | ||
Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. | Q45826312 | ||
A randomized, double-blind, controlled study and pooled analysis of two identical trials of fermented milk containing probiotic Bifidobacterium lactis CNCM I-2494 in healthy women reporting minor digestive symptoms | Q46116511 | ||
Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis | Q46143449 | ||
Culture-dependent and culture-independent qualitative analysis of probiotic products claimed to contain bifidobacteria | Q46578797 | ||
Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates | Q47370646 | ||
Effect of mother's weight on infant's microbiota acquisition, composition, and activity during early infancy: a prospective follow-up study initiated in early pregnancy. | Q47414505 | ||
Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells | Q47945739 | ||
Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. | Q48492553 | ||
The burden of gastrointestinal and liver diseases, 2006. | Q50785635 | ||
Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. | Q51010528 | ||
New-onset asthma and the effect of environment and occupation among farming and nonfarming rural subjects | Q51021301 | ||
The microbiota-gut-brain axis: learning from intestinal bacteria? | Q51889499 | ||
Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial | Q53184076 | ||
Deep 16S rRNA metagenomics and quantitative PCR analyses of the premature infant fecal microbiota. | Q54310247 | ||
Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. | Q54341852 | ||
Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease. | Q54486654 | ||
Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease | Q57129932 | ||
What is the role of the enteric commensal flora in IBD? | Q57241171 | ||
A Randomized Formula Controlled Trial of Bifidobacterium lactis and Streptococcus thermophilus for Prevention of Antibiotic-Associated Diarrhea in Infants | Q58227623 | ||
Influence of early gut microbiota on the maturation of childhood mucosal and systemic immune responses | Q58590807 | ||
Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles | Q59880418 | ||
Analysis of the Fecal Microbiota of Irritable Bowel Syndrome Patients and Healthy Controls with Real-Time PCR | Q63242386 | ||
Fecal beta-D-galactosidase production and Bifidobacteria are decreased in Crohn's disease | Q73285248 | ||
Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing | Q73375788 | ||
Comparison of mucosal adhesion and species identification of bifidobacteria isolated from healthy and allergic infants | Q73428420 | ||
Differences in Bifidobacterium flora composition in allergic and healthy infants | Q74181054 | ||
Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants | Q81224806 | ||
Influence of Bifidobacterium longum BB536 intake on faecal microbiota in individuals with Japanese cedar pollinosis during the pollen season | Q81347272 | ||
Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota | Q81402999 | ||
Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome | Q82443786 | ||
Antibiotic Therapy for the Irritable Bowel Syndrome | Q83133047 | ||
Effect of probiotic Bifidobacterium longum BB536 [corrected] in relieving clinical symptoms and modulating plasma cytokine levels of Japanese cedar pollinosis during the pollen season. A randomized double-blind, placebo-controlled trial | Q83320099 | ||
Beneficial Effects of Long‐Term Consumption of a Probiotic Combination of Lactobacillus casei Shirota and Bifidobacterium breve Yakult May Persist After Suspension of Therapy in Lactose‐Intolerant Patients | Q83609570 | ||
Beneficial Effects of Probiotic Bifidobacterium and Galacto-Oligosaccharide in Patients with Ulcerative Colitis: A Randomized Controlled Study | Q83986587 | ||
The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases | Q84002918 | ||
The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis | Q84290217 | ||
Synbiotics prevent asthma-like symptoms in infants with atopic dermatitis | Q84437254 | ||
Immune-modulatory effect of probiotic Bifidobacterium lactis NCC2818 in individuals suffering from seasonal allergic rhinitis to grass pollen: an exploratory, randomized, placebo-controlled clinical trial | Q85856203 | ||
Hepatic encephalopathy involves interactions among the microbiota, gut, brain | Q87162989 | ||
P433 | issue | 41 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 15163-15176 | |
P577 | publication date | 2014-11-07 | |
P13046 | publication type of scholarly work | review article | Q7318358 |
P1433 | published in | World Journal of Gastroenterology | Q15708885 |
P1476 | title | Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis | |
P478 | volume | 20 |
Q35342352 | A Novel Lactobacillus casei LP1 Producing 1,4-Dihydroxy-2-Naphthoic Acid, a Bifidogenic Growth Stimulator |
Q52690219 | A Walnut-Enriched Diet Affects Gut Microbiome in Healthy Caucasian Subjects: A Randomized, Controlled Trial |
Q55262976 | A commensal Bifidobacterium longum strain improves gluten-related immunopathology in mice through expression of a serine protease inhibitor. |
Q39785370 | A proteomic approach towards understanding the cross talk between Bacteroides fragilis and Bifidobacterium longum in coculture. |
Q38865456 | Acid-Suppressive Therapy and Risk of Infections: Pros and Cons |
Q91595404 | Alcohol pretreatment of stools effect on culturomics |
Q41109751 | Analysis of newly detected tetracycline resistance genes and their flanking sequences in human intestinal bifidobacteria |
Q90147652 | Anti-colon cancer activity of Bifidobacterium metabolites on colon cancer cell line SW742 |
Q26742179 | Bifidobacteria and Butyrate-Producing Colon Bacteria: Importance and Strategies for Their Stimulation in the Human Gut |
Q46310354 | Bifidobacteria exert species-specific effects on constipation in BALB/c mice |
Q61707789 | Bifidobacterium animalis subspecies lactis modulates the local immune response and glucose uptake in the small intestine of juvenile pigs infected with the parasitic nematode Ascaris suum |
Q39431579 | Butyric acid - a well-known molecule revisited |
Q89782935 | CME |
Q42369902 | Characterization and Exploitation of CRISPR Loci in Bifidobacterium longum. |
Q47222584 | Comparative genome and methylome analysis reveals restriction/modification system diversity in the gut commensal Bifidobacterium breve |
Q55668908 | Comparative genomics and genotype-phenotype associations in Bifidobacterium breve. |
Q91813141 | Comparative genomics of Bifidobacterium species isolated from marmosets and humans |
Q35913949 | Comparison of Fecal Microbiota between German Holstein Dairy Cows with and without Left-Sided Displacement of the Abomasum |
Q36757913 | Comparison of probiotic lactobacilli and bifidobacteria effects, immune responses and rotavirus vaccines and infection in different host species |
Q64118491 | Comprehensive Kinetic Survey of Intestinal, Extra-Intestinal and Systemic Sequelae of Murine Ileitis Following Peroral Low-Dose Infection |
Q36502458 | Construction of a Recombinant Leuconostoc mesenteroides CJNU 0147 Producing 1,4-Dihydroxy-2-Naphthoic Acid, a Bifidogenic Growth Factor |
Q54264376 | Current understanding of microbiota- and dietary-therapies for treating inflammatory bowel disease. |
Q93103397 | Development of experimental pneumococcal vaccine for mucosal immunization |
Q37673181 | Dietary Fiber and the Human Gut Microbiota: Application of Evidence Mapping Methodology |
Q55491800 | Disbiome database: linking the microbiome to disease. |
Q42694558 | Distinctive Gut Microbiota Is Associated with Diarrheagenic Escherichia coli Infections in Chilean Children |
Q59803211 | Draft Genome Sequence of Bifidobacterium longum BB-79, a Strain That Produces Acid Exopolysaccharide |
Q33755362 | Edible Plants and Their Influence on the Gut Microbiome and Acne. |
Q39634400 | Effect of a Ropy Exopolysaccharide-Producing Bifidobacterium animalis subsp. lactis Strain Orally Administered on DSS-Induced Colitis Mice Model. |
Q92339809 | Effect of a bioactive product SEL001 from Lactobacillus sakei probio65 on gut microbiota and its anti-colitis effects in a TNBS-induced colitis mouse model |
Q89027309 | Effect of direct-fed microbials on culturable gut microbiotas in broiler chickens: a meta-analysis of controlled trials |
Q94555106 | Effective bifidogenic growth factors cyclo-Val-Leu and cyclo-Val-Ile produced by Bacillus subtilis C-3102 in the human colonic microbiota model |
Q36081669 | Effects of Arabinoxylan and Resistant Starch on Intestinal Microbiota and Short-Chain Fatty Acids in Subjects with Metabolic Syndrome: A Randomised Crossover Study |
Q99711480 | Effects of Bifidobacterium longum Subsp. infantis CECT 7210 and Lactobacillus rhamnosus HN001, Combined or Not With Oligofructose-Enriched Inulin, on Weaned Pigs Orally Challenged With Salmonella Typhimurium |
Q89945565 | Effects of Eimeria tenella infection on the barrier damage and microbiota diversity of chicken cecum |
Q58580538 | Effects of Probiotic as an Alternative of Antibiotics on Digestive Enzymes Activity and Intestinal Integrity of Piglets |
Q41755806 | Effects of exposure to bisphenol A and ethinyl estradiol on the gut microbiota of parents and their offspring in a rodent model |
Q35749993 | Emerging potential of natural products for targeting mucins for therapy against inflammation and cancer. |
Q57677268 | Enhanced butyrate formation by cross-feeding betweenFaecalibacterium prausnitziiandBifidobacterium adolescentis |
Q39336917 | Evidence of the Anti-Inflammatory Effects of Probiotics and Synbiotics in Intestinal Chronic Diseases |
Q38601534 | Evolution of gut Bifidobacterium population in healthy Japanese infants over the first three years of life: a quantitative assessment. |
Q37685219 | Exploration of the effect of probiotics supplementation on intestinal microbiota of food allergic mice |
Q47104976 | Extracts from Hericium erinaceus relieve inflammatory bowel disease by regulating immunity and gut microbiota |
Q30986751 | Faecal microbiota transplant for recurrent Clostridium difficile infection using long-term frozen stool is effective: clinical efficacy and bacterial viability data |
Q88453320 | Function, Regulation, and Pathophysiological Relevance of the POT Superfamily, Specifically PepT1 in Inflammatory Bowel Disease |
Q61798328 | Functional gastrointestinal disorders and gut-brain axis: What does the future hold? |
Q41108400 | Gene Replacement and Fluorescent Labeling to Study the Functional Role of Exopolysaccharides in Bifidobacterium animalis subsp. lactis. |
Q47745576 | Genomic diversity and distribution of Bifidobacterium longum subsp. longum across the human lifespan |
Q47133573 | Global transcriptional landscape and promoter mapping of the gut commensal Bifidobacterium breve UCC2003. |
Q35694201 | Glycolysis for Microbiome Generation |
Q28071697 | Gut Bifidobacteria Populations in Human Health and Aging |
Q91962106 | Gut Microbiome: Profound Implications for Diet and Disease |
Q64119808 | Gut Microbiota Profiles in Nonalcoholic Fatty Liver Disease and Its Possible Impact on Disease Progression Evaluated with Transient Elastography: Lesson Learnt from 60 Cases |
Q92073238 | Gut Microbiota and the Alteration of Immune Balance in Skin Diseases: From Nutraceuticals to Fecal Transplantation |
Q92570841 | Health Benefits of Lactobacillus gasseri CP2305 Tablets in Young Adults Exposed to Chronic Stress: A Randomized, Double-Blind, Placebo-Controlled Study |
Q52374120 | Human Gut Microbiota and Gastrointestinal Cancer |
Q92711871 | Identification of plasmalogens in Bifidobacterium longum, but not in Bifidobacterium animalis |
Q55497696 | Ileum terminal antibiotic infusion affects jejunal and colonic specific microbial population and immune status in growing pigs. |
Q46317344 | Impact of coculturing Bifidobacterium animalis subsp. lactis HN019 with yeasts on microbial viability and metabolite formation |
Q26999090 | Individualized medicine and the microbiome in reproductive tract |
Q64102240 | Interactions Between the Gut Microbiota and the Host Innate Immune Response Against Pathogens |
Q42372827 | Intestinal Microbiota Changes in Mice Lacking Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) - Bifidobacteria Make the Difference |
Q49685739 | Intestinal barrier and gut microbiota: Shaping our immune responses throughout life |
Q59791815 | Intestinal microbiota mediates Enterotoxigenic Escherichia coli-induced diarrhea in piglets |
Q41943716 | Intestinal microbiota: a potential target for the treatment of postmenopausal osteoporosis |
Q43075314 | Is irritable bowel syndrome an infectious disease? |
Q92240445 | Maternal Fish Consumption in Pregnancy Is Associated with a Bifidobacterium-Dominant Microbiome Profile in Infants |
Q92358231 | Metabolism of 3-[5'-deoxy-5'-(dimethylarsinoyl)-β-ribofuranosyloxy]-2-hydroxypropylene glycol in an artificial digestive system |
Q46422313 | Metagenomics approach to the study of the gut microbiome structure and function in zebrafish Danio rerio fed with gluten formulated diet |
Q35872112 | Microbial translocation and microbiome dysbiosis in HIV-associated immune activation |
Q28072437 | Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate |
Q90733147 | Murine Fecal Microbiota Transplantation Alleviates Intestinal and Systemic Immune Responses in Campylobacter jejuni Infected Mice Harboring a Human Gut Microbiota |
Q26748527 | Novel Insights into the Pathogenesis of Hirschsprung's-associated Enterocolitis |
Q90383698 | Oral Probiotics Alleviate Intestinal Dysbacteriosis for People Receiving Bowel Preparation |
Q33909976 | Potential and active functions in the gut microbiota of a healthy human cohort |
Q54941242 | Probiotic Lactobacillus sakei proBio-65 Extract Ameliorates the Severity of Imiquimod Induced Psoriasis-Like Skin Inflammation in a Mouse Model. |
Q38946102 | Probiotics for people with hepatic encephalopathy |
Q38921638 | Probiotics, gut microbiota, and their influence on host health and disease. |
Q41037109 | Production of a Functional Frozen Yogurt Fortified with Bifidobacterium spp. |
Q38461139 | Products for the treatment of inflammatory bowel disease: a patent review (2013 - 2014). |
Q50074955 | Psycho-Neuro-Endocrine-Immunology: A Psychobiological Concept |
Q36691129 | Regulatory effect of paraprobiotic Lactobacillus gasseri CP2305 on gut environment and function |
Q91612102 | Role of the intestinal microbiome in colorectal cancer surgery outcomes |
Q39000441 | Role of vitamin D on gut microbiota in cystic fibrosis |
Q35730471 | Serum Levels of Lipopolysaccharide and 1,3-β-D-Glucan Refer to the Severity in Patients with Crohn's Disease. |
Q60936005 | Stability and resilience of the intestinal microbiota in children in daycare - a 12 month cohort study |
Q92322341 | Structural basis for broad substrate specificity of UDP-glucose 4-epimerase in the human milk oligosaccharide catabolic pathway of Bifidobacterium longum |
Q92570756 | Targeting Microbiota: What Do We Know about It at Present? |
Q36137294 | Taxa of the Nasal Microbiome Are Associated with Influenza-Specific IgA Response to Live Attenuated Influenza Vaccine |
Q47122608 | The Association between Modulating Inflammatory Cytokines and Constipation of Geriatrics in Iran |
Q35784228 | The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial |
Q46265536 | The First Microbial Colonizers of the Human Gut: Composition, Activities, and Health Implications of the Infant Gut Microbiota. |
Q64997664 | The Immunomodulatory Properties of Extracellular Vesicles Derived from Probiotics: A Novel Approach for the Management of Gastrointestinal Diseases. |
Q93108849 | The Intestinal Fate of Citrus Flavanones and Their Effects on Gastrointestinal Health |
Q58098051 | The Microbiotic Highway to Health-New Perspective on Food Structure, Gut Microbiota, and Host Inflammation |
Q61837805 | The Neonatal Microbiome and Its Partial Role in Mediating the Association between Birth by Cesarean Section and Adverse Pediatric Outcomes |
Q92094167 | The Nlrp3 inflammasome as a "rising star" in studies of normal and malignant hematopoiesis |
Q51736365 | The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression |
Q34474989 | The dormant blood microbiome in chronic, inflammatory diseases |
Q33911910 | The essential genomic landscape of the commensal Bifidobacterium breve UCC2003. |
Q58264156 | The inflammation regulation effects ofEnterococcus faeciumHDRsEf1 on human enterocyte-like HT-29 cells |
Q38769870 | The pediatric Rome IV criteria: what's new? |
Q35661982 | The relationship between phenolic compounds from diet and microbiota: impact on human health. |
Q41923884 | The role of polymorphonuclear neutrophils during HIV-1 infection |
Q48206498 | Toll-like receptors 2 and 4 exert opposite effects on the contractile response induced by serotonin in mouse colon: role of serotonin receptors. |
Q42337445 | Window-of-opportunity: neonatal gut microbiota and atopy |
Search more.